Your browser doesn't support javascript.
loading
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin, Shukui; Chen, Minshan; Cheng, Ann-Lii; Kaseb, Ahmed O; Kudo, Masatoshi; Lee, Han Chu; Yopp, Adam C; Zhou, Jian; Wang, Lu; Wen, Xiaoyu; Heo, Jeong; Tak, Won Young; Nakamura, Shinichiro; Numata, Kazushi; Uguen, Thomas; Hsiehchen, David; Cha, Edward; Hack, Stephen P; Lian, Qinshu; Ma, Ning; Spahn, Jessica H; Wang, Yulei; Wu, Chun; Chow, Pierce K H.
Afiliação
  • Qin S; Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
  • Chen M; Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Cheng AL; National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.
  • Kaseb AO; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kudo M; Kindai University, Osaka, Japan.
  • Lee HC; Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Yopp AC; Department of Surgery, Division of Surgical Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Zhou J; Zhongshan Hospital, Fudan University, Shanghai, China.
  • Wang L; Fudan University Shanghai Cancer Center, Shanghai, China.
  • Wen X; 1st Hospital of Jilin University, Jilin, China.
  • Heo J; College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
  • Tak WY; Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
  • Nakamura S; Himeji Red Cross Hospital, Hyogo, Japan.
  • Numata K; Yokohama City University Medical Center, Yokohama, Japan.
  • Uguen T; Hôpital de Pontchaillou, Rennes, France.
  • Hsiehchen D; Department of Internal Medicine, Division of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Cha E; Genentech, South San Francisco, CA, USA.
  • Hack SP; Genentech, South San Francisco, CA, USA.
  • Lian Q; Genentech, South San Francisco, CA, USA.
  • Ma N; Genentech, South San Francisco, CA, USA.
  • Spahn JH; Genentech, South San Francisco, CA, USA.
  • Wang Y; Fudan University Shanghai Cancer Center, Shanghai, China; Genentech, South San Francisco, CA, USA.
  • Wu C; Roche (China) Holding, Shanghai, China.
  • Chow PKH; National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, Singapore. Electronic address: pierce.chow@duke-nus.edu.sg.
Lancet ; 402(10415): 1835-1847, 2023 11 18.
Article em En | MEDLINE | ID: mdl-37871608
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Adult / Humans Idioma: En Revista: Lancet Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Adult / Humans Idioma: En Revista: Lancet Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China